Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Elicio Therapeutics Inc (NQ: ELTX ) 4.800 -0.200 (-4.00%) Streaming Delayed Price Updated: 9:57 AM EDT, Oct 10, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Elicio Therapeutics Inc < Previous 1 2 3 Next > 12 Health Care Stocks Moving In Tuesday's Pre-Market Session October 01, 2024 Via Benzinga Elicio Therapeutics Reports Inducement Grants September 17, 2024 From Elicio Therapeutics Inc. Via GlobeNewswire Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines September 13, 2024 From Elicio Therapeutics Inc. Via GlobeNewswire Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference August 28, 2024 From Elicio Therapeutics Inc. Via GlobeNewswire First Patient Dosed In Phase 2 Study Of Elicio Therapeutics’ ELI-002 7P February 01, 2024 --News Direct-- Via News Direct ELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q2 2024 August 13, 2024 ELTX stock results show that Elicio Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates August 13, 2024 From Elicio Therapeutics Inc. Via GlobeNewswire Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note August 12, 2024 From Elicio Therapeutics Inc. Via GlobeNewswire Why Is Cancer Vaccine Developer Elicio Therapeutics Stock Trading Lower On Friday? June 28, 2024 Elicio Therapeutics announced promising preliminary data from the AMPLIFY-7P Phase 1a study of ELI-002 7P, showing extended median disease-free survival in patients with mKRAS-driven solid tumors. Via Benzinga Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering June 28, 2024 From Elicio Therapeutics Inc. Via GlobeNewswire Why Is Elicio Therapeutics (ELTX) Stock Down 36% Today? June 28, 2024 Elicio Therapeutics stock is down on Friday after the company announced a proposed public offering for shares of ELTX this morning. Via InvestorPlace Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday June 28, 2024 Pre-market stock movers are a hot topic on Friday and we're breaking down all of the latest news sending shares higher and lower! Via InvestorPlace Elicio Therapeutics Announces Proposed Public Offering June 27, 2024 From Elicio Therapeutics Inc. Via GlobeNewswire Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P June 27, 2024 ELI-002 7P administered as a monotherapy at the Phase 2 dose shows preliminary encouraging Disease-Free Survival data in pancreatic ductal adenocarcinoma From Elicio Therapeutics Inc. Via GlobeNewswire Elicio Therapeutics Unveils Promising Phase 1a Data For ELI-002 7P In mKRAS Tumors June 10, 2024 Elicio Therapeutics Unveils Promising Phase 1a Data For ELI-002 7P In mKRAS Tumors Via News Direct 12 Health Care Stocks Moving In Thursday's Intraday Session May 16, 2024 Via Benzinga ELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q1 2024 May 15, 2024 ELTX stock results show that Elicio Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Elicio Therapeutics (NASDAQ: ELTX) Makes Strides In Growing Cancer Vaccination Industry April 11, 2024 Elicio Therapeutics (NASDAQ: ELTX) Makes Strides In Growing Cancer Vaccination Industry Via News Direct 12 Health Care Stocks Moving In Friday's After-Market Session April 05, 2024 Via Benzinga Unlocking the Power of Immunotherapy: Elicio Therapeutics’ (NASDAQ: ELTX) Novel AMP Platform April 05, 2024 --News Direct-- Via News Direct Topics Death Exposures Death ELTX Stock Earnings: Elicio Therapeutics Misses EPS for Q4 2023 April 02, 2024 ELTX stock results show that Elicio Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. Via InvestorPlace Benzinga's 2024 Virtual Healthcare: What's Next In Health? March 19, 2024 The 2024 Benzinga Virtual Healthcare Summit brings together top healthcare professionals and companies to discuss industry trends, advancements in technology, and the future of healthcare. Don't miss... Via Benzinga 12 Health Care Stocks Moving In Monday's Intraday Session March 18, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session March 18, 2024 Via Benzinga 12 Health Care Stocks Moving In Thursday's Pre-Market Session February 08, 2024 Via Benzinga 12 Health Care Stocks Moving In Wednesday's Intraday Session February 07, 2024 Via Benzinga 12 Health Care Stocks Moving In Wednesday's Pre-Market Session February 07, 2024 Via Benzinga Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating Power Of Amphiphile-Immunotherapy February 06, 2024 --News Direct-- Via News Direct Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference February 05, 2024 From Elicio Therapeutics Inc. Via GlobeNewswire Elicio Therapeutics Announces Publication Of Preclinical Data Demonstrating Power Of Amphiphile-Immunotherapy February 05, 2024 A clinical-stage biotechnology company has published promising preclinical data in Cancer Immunology Research, a journal of the American Association for Cancer Research (AACR). Via Benzinga < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.